Announced
Completed
Financials
Sources
Press Release
AbbVie -
Press release
AbbVie -
Deal Page
Abbvie -
Investor Presentation
Abbvie -
RNS Announcement
AbbVie -
Press release
AbbVie -
Letter to shareholders
Allergan -
Press release
AbbVie -
Leadership changes
AbbVie -
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
AbbVie -
Completion Announcement
AbbVie -
Completion Announcement
Allergan -
Tags
Acquisition
Ireland
Pharmaceuticals
pharmaceuticals
Friendly
Public
Single Bidder
Majority
Completed
Synopsis
AbbVie, a researcher and developer of pharmaceutical products, completed the acquisition of Allergan, a manufacturer of speciality pharmaceuticals for $63bn. Allergan shareholders received 0.8660 AbbVie Shares and $120.30 in cash for each Allergan share, for a total consideration of $193.23 per Allergan share. "We are pleased to reach this important milestone for the Company, its employees, shareholders and the patients we serve. Our new Allergan colleagues should be commended for all their efforts, along with those of our own employees, to achieve this turning point for our Company. I am proud of both organizations and look forward to the opportunities ahead," Richard A. Gonzalez, AbbVie CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.